Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
26. |
ECCT/24/02/07 | CO-SAM An adaptive multi-arm trial to improve clinical outcomes among children recovering from complicated severe acute malnutrition (CO-SAM) |
Principal Investigator(s) 1. Benson Singa Site(s) in Kenya 1. Homabay County Referral hospital (Homa Bay county) 2. Migori County Referral Hospital (Migori county) 3. Mbagathi County Referral Hospital (Nairobi City county) 4. Coast General Teaching and Referral Hospital (Mombasa county) |
View |
27. |
ECCT/24/02/10 | IMBrave A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA |
Principal Investigator(s) 1. Dr. Pauline Njoki Njiraini Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
View |
28. |
ECCT/24/02/06 | INAVO122 A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in combination with Phesgo as maintenance therapy after first line induction therapy in participants with PIK3CA‐mutated HER2‐positive locally advanced or metastatic breast cancer |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
View |
29. |
ECCT/24/02/09 | pionERA This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
View |
30. |
ECCT/23/12/02 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL) |
Principal Investigator(s) 1. Dr. Maricianah Onono Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 2. Walter Reed Army Institute of Research -Kericho Site (Kericho county) 3. KEMRI CCR – Butere Clinical Research Centre (Kakamega county) 4. Siaya County Referral Hospital (SCRH) (Siaya county) 5. Kenya Medical Research Institute Center for Microbiology Research (CMR) (Kisumu county) 6. KAVI - Institute of Clinical Research (KAVI - ICR) (Nairobi City county) 7. Kombewa Clinical Research Center, KEMRI, (Kisumu county) |
View |